Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT00477724
Other study ID # REHA/CTEPH
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 2007
Est. completion date December 2023

Study information

Verified date July 2022
Source Heidelberg University
Contact Ekkehard Gruenig, MD
Phone +49 6221 396 80 53
Email ekkehard.gruenig@med.uni-heidelberg.de
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Severe CTEPH leads to an impaired physical capacity and a restricted quality of life and poor prognosis. Pulmonary endarterectomy represents the best choice as therapy, when the thrombi are located in the central pulmonary vessels and therefore can be operated. By this operation the pulmonary artery pressure can be normalised and the patients' survival improved. Up to now, after successful endarterectomy patients only receive anticoagulation. Despite operation many patients remain symptomatic and are restricted in their physical capacity. Therefore a hypothesis of this project is that most of the patients, even after successful operation, show peripheral vascular remodelling with a ventilation-perfusion mismatch and elevated pulmonary pressure during exercise. In this study we aim to analyse how many patients with CTEPH after endarterectomy show elevated pulmonary artery pressures at rest or during exercise and are limited in their physical capacity, hemodynamics, oxygen uptake and quality of life and need further therapy. Another aim is to examine whether exercise and respiratory therapy may improve the patients postoperatively. Therefore 30 patients with CTEPH > six months after endarterectomy, with ongoing restricted exercise capacity shall be included. After baseline examination in the University hospital Heidelberg the patients receive exercise and respiratory therapy for three weeks. The patients will receive further examinations at the end of rehabilitation after 3 weeks and after 15 weeks. All examinations include medical history, family history, physical examination, ECG and echocardiography at rest and during exercise, cardiopulmonary exercise testing, assessment of the respiratory muscle strength, the SF-36 questionnaire for quality of life, laboratory testing and MRI. Rehabilitation will be conducted in the clinic for rehabilitation Koenigstuhl, Heidelberg. Participants will be randomised into two groups, a control group receiving a conventional therapy for three weeks, in which physical exertion is to be avoided and a training group with additional exercise and respiratory therapy.


Recruitment information / eligibility

Status Recruiting
Enrollment 35
Est. completion date December 2023
Est. primary completion date December 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - A Screening 1. Informed consent 2. Men and women 18 - 75 years 3. Patients = 6 months after endarterectomy because of chronic thromboembolic pulmonary hypertension (CTEPH) - B Training See A + all patients who showed a restricted physical capacity in the screening: - Latent pulmonary hypertension - Restricted physical capacity Exclusion Criteria: 1. Pregnancy or lactation 2. Change in medication during the last 2 months 3. Patients with signs of right heart decompensation 4. Disease which affects the gait 5. Unclear diagnosis 6. Acute illness, infection, fever 7. Severe lung diseases with FEV1 <50% and TLC< 70% of reference

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
exercise and respiratory therapy
exercise and respiratory therapy for three weeks in-hospital and 15 weeks at home
Other:
sedentary control group
control group with no specific training

Locations

Country Name City State
Germany Thoraxclinic at the University Hospital Heidelberg Heidelberg Baden-Wuerttemberg

Sponsors (1)

Lead Sponsor Collaborator
Heidelberg University

Country where clinical trial is conducted

Germany, 

References & Publications (1)

Mereles D, Ewert R, Lodziewski S, Borst MM, Benz A, Olschewski H, Grünig E. Effect of inhaled iloprost during off-medication time in patients with pulmonary arterial hypertension. Respiration. 2007;74(5):498-502. Epub 2007 Apr 20. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in 6-Minute walking test after 3 and 15 weeks compared to baseline
Primary Change in quality of life baseline and 15 weeks
Secondary physical capacity in the ergometer test baseline, 3 and 15 weeks
Secondary change of lung function during 6-minute walking test baseline, 3 and 15 weeks
Secondary noninvasive hemodynamic parameters baseline, 3 and 15 weeks
Secondary change of systolic pulmonary arterial pressure at rest and during exercise baseline, 3 and 15 weeks
Secondary change of WHO functional class baseline, 3 and 15 weeks
Secondary change of perfusion parameters (MRI) baseline, 3 and 15 weeks
Secondary change of respiratory muscle function baseline and 15 weeks
Secondary change of NTproBNP baseline, 3 and 15 weeks
See also
  Status Clinical Trial Phase
Withdrawn NCT01950585 - Hydroxyurea in Pulmonary Arterial Hypertension Early Phase 1
Completed NCT00527163 - Role of Nitric Oxide in Malaria
Completed NCT03649932 - Enteral L Citrulline Supplementation in Preterm Infants - Safety, Efficacy and Dosing Phase 1
Recruiting NCT04554160 - Arrhythmias in Pulmonary Hypertension Assessed by Continuous Long-term Cardiac Monitoring
Enrolling by invitation NCT03683186 - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension Phase 3
Completed NCT01894035 - Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation
Not yet recruiting NCT04083729 - Persistent Pulmonary Hypertension After Percutaneous Mitral Commissurotomy N/A
Completed NCT02821156 - Study on the Use of Inhaled NO (iNO) N/A
Terminated NCT02243111 - Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc) by Ultrasound N/A
Completed NCT02216279 - Phase-II Study of the Use of PulmoBind for Molecular Imaging of Pulmonary Hypertension Phase 2
Terminated NCT02246348 - Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc) N/A
Recruiting NCT01913847 - Safety and Efficacy Study of HGP1207 in Patients With Pulmonary Hypertension Phase 3
Completed NCT01615484 - Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability N/A
Completed NCT06240871 - Contrast Enhanced PA Pressure Measurements
Completed NCT02377934 - Evaluation of Radiation Induced Pulmonary Hypertension Using MRI in Stage III NSCLC Patients Treated With Chemoradiotherapy. A Pilot Study
Recruiting NCT01091012 - Effectiveness of the Vasodilator Test With Revatio, Made in Patients With Acute Pulmonary Hypertension Phase 3
Completed NCT01463514 - Noninvasive Determination of Cerebral Tissue Oxygenation in Pulmonary Hypertension N/A
Completed NCT00739375 - The Effect of Blood Flow in the Maturing Arteriovenous Access for Hemodialysis on the Development of Pulmonary Hypertension. Phase 1
Completed NCT01484899 - Smoking: a Risk Factor for Pulmonary Arterial Hypertension? N/A
Completed NCT02275793 - The Regulation of Pulmonary Vascular Resistance in Patients With Heart Failure